Ureteral stents market seen reaching $1.26 billion by 2035

Market Research Future projects the global ureteral stents market will rise from $711.8 million in 2026 to $1.26 billion by 2035, driven by kidney stone cases, biodegradable stent innovation and more outpatient procedures. The forecast points to faster growth in biodegradable products and ambulatory surgical centers as reimbursement and clinical preferences shift.

Why it matters: - The ureteral stents market is tied to rising demand for minimally invasive urology care, especially for kidney stones and tumor-related obstruction. - Lower-cost outpatient procedures and biodegradable devices could reduce follow-up surgeries and change how hospitals and ambulatory centers buy stents. - The market outlook signals where medtech spending is shifting across products, materials and care settings.

What happened: - Market Research Future projected the global ureteral stents market will reach $1,259.9 million by 2035, up from $711.8 million in 2026. - The forecast implies a 6.55% compound annual growth rate from 2026 to 2035. - The market base was estimated at $668.0 million in 2025. - The release said growth is being driven by kidney stone prevalence, biodegradable stent innovation and migration to ambulatory surgical centers. - The report included a free sample request and customization request.

The details: - Kidney stone prevalence in the U.S. is approximately 10% of the adult population, according to the release. - The report said women under 60 are the fastest-growing patient cohort. - The WHO is projecting a 25% increase in nephrolithiasis cases across South and Southeast Asia by 2030, according to the release. - Biodegradable stents are designed to resorb within 4 to 8 weeks after surgery. - The U.S. FDA granted 510(k) clearance to the RELIEF biodegradable ureteral stent in January 2024 for vesicoureteral reflux prevention. - CMS expanded outpatient reimbursement codes for ureteral stent procedures in January 2025. - Ambulatory surgical centers are cited as offering 30% to 45% cost savings versus hospital-based settings. - North American ambulatory surgical center capacity grew 8.2% year over year in 2024. - Double pigtail stents held about 42.1% of revenue in 2025. - Biodegradable stents were the fastest-growing product segment, with a projected 10.75% CAGR from 2026 to 2035. - Polyurethane held about 44.8% of material revenue in the base year. - Silicone generated $148.3 million in 2025. - Kidney stones accounted for about 56.8% of revenue in 2025. - Tumor-related obstruction was the fastest-growing application, projected at an 8.95% CAGR. - Hospitals held about 63.0% of end-user share in 2025. - Ambulatory surgical centers were the fastest-growing end-user segment, projected at an 8.70% CAGR. - North America led the market with about 38.5% share in 2025. - The U.S. generated about 72% of North American revenue. - Europe was the second-largest regional market at $181.7 million in 2025. - Asia-Pacific was the fastest-growing region, with an 8.15% CAGR. - The Middle East and Africa region is projected to grow at 7.20% CAGR. - South America reached $41.4 million in 2025. - The top five companies held an estimated 48% to 55% combined share. - Boston Scientific, Coloplast, Cook Medical and Olympus were listed among the key companies.

Between the lines: - The forecast shows a market moving from procedure volume alone to a mix of clinical efficiency, material innovation and reimbursement strategy. - Biodegradable stents may be the clearest margin opportunity because they reduce the need for removal procedures and associated complications. - The strongest regional growth is concentrated in Asia-Pacific, where hospital expansion and insurance coverage are widening access. - Competition appears moderate, leaving room for product differentiation through coatings, resorbable materials and ASC-focused kits.

What's next: - The report expects precision biodegradable stent systems and AI-assisted selection tools to become more important through 2030. - It forecast that about 40% of newly diagnosed kidney stone patients could undergo CT urography staging followed by matched stent selection by 2030. - Regulatory clearances for next-generation biodegradable designs are expected to keep accelerating product turnover. - The market is likely to keep shifting toward outpatient care and single-use stenting kits as reimbursement favors lower-cost settings.

The bottom line: - Ureteral stents are moving toward a faster-growing, more outpatient-driven market where biodegradable materials and procedure simplification could reshape buying patterns through 2035.